专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2004337321A Walker doubling as buggy 审中-公开
公开(公告)号：JP2004337321A
公开(公告)日：2004-12-02
申请号：JP2003136728
申请日：2003-05-15
申请人： Yumi Matsui , 由実松居
发明人： MATSUI YUMI , TEJIMA NORIYUKI
IPC分类号： B62B7/12 , A61H3/04
摘要： PROBLEM TO BE SOLVED: To provide a means for reducing a care-giver's burden and promoting a child's waking ability and curiosity, by solving the following problems: the care-giver requires much labor for carrying a buggy or a baby carriage and a walker or transferring the child between the buggy or the baby carriage and the walker, when the buggy or the baby carriage and the walker are separately bought and properly used; the child as a user cannot transfer to the walker at once due to the care-giver's convenience etc. even if the child wants to walk by using his/her own feet alone; and the child may reduce his/her curiosity about surrounding things.
SOLUTION: This walker doubling as the buggy is equipped with a seat surface for allowing the user to seat himself/herself, and a backrest for supporting the user's body when he/she seats himself/herself. The walker doubling as the buggy can be used as the buggy or the baby carriage; the seat surface can be housed by being moved or deformed; and the walker doubling as the buggy can be used as a walker when the seat surface is housed.
COPYRIGHT: (C)2005,JPO&NCIPI

2. 发明申请

US20110003787A1 NOVEL PHENYLPYRROLE DERIVATIVE 有权
标题翻译：新颖的灵性衍生物
公开(公告)号：US20110003787A1
公开(公告)日：2011-01-06
申请号：US12843348
申请日：2010-07-26
申请人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
发明人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
IPC分类号： A61K31/427 , C07D417/04 , C07D413/14 , C07D413/12 , A61P3/10 , A61K31/501 , A61K31/4439 , A61K31/428 , C07D403/04 , A61K31/497 , C07D207/34 , A61K31/40 , C07D413/04 , A61K31/422 , A61K31/5355 , C07D417/14 , A61K31/5377
CPC分类号： C07D413/14 , C07D207/333 , C07D207/335 , C07D207/337 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D417/14
摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
摘要翻译：本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成取代具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同）或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

3. 发明授权

US5781372A Axial resonance attenuating apparatus for rotation drum apparatus having flexible rod-shaped linking members 失效
标题翻译：具有柔性杆形连接件的旋转鼓装置的轴向共振衰减装置
公开(公告)号：US5781372A
公开(公告)日：1998-07-14
申请号：US641174
申请日：1996-04-30
申请人： Toshiharu Miyago , Yumi Matsui , Yoshikazu Nishida
发明人： Toshiharu Miyago , Yumi Matsui , Yoshikazu Nishida
IPC分类号： G11B5/52 , F16F15/121 , G11B5/53 , G11B15/61 , G11B33/08 , H02K7/04 , G11B5/027
CPC分类号： G11B33/08 , F16F15/1215 , G11B15/61 , G11B5/53 , H02K7/04
摘要： An axial resonance attenuating apparatus is formed by a disk-shaped attaching member, which is attached to a rotation shaft of a rotation drum apparatus or one of mass objects which are fixed to the both ends of the rotation shaft. A ring-shaped weight is disposed outside the attaching member, and a linking member which is formed by a plurality of straight and flexible support rods partially links the weight and the attaching member. The respective members are formed as one unit by an acrylonitrile-butadiene-styrene copolymer (ABS resin).
摘要翻译：轴向共振衰减装置由安装在旋转鼓装置的旋转轴或固定在旋转轴的两端的质量物体之一的盘形安装构件形成。环形重物设置在安装构件的外侧，并且由多个直的和柔性的支撑杆形成的连接构件部分地连接重物和附接构件。各个构件通过丙烯腈 - 丁二烯 - 苯乙烯共聚物（ABS树脂）形成一个单元。

4. 发明授权

US08415359B2 Phenylpyrrole derivative 有权
标题翻译：苯基吡咯衍生物
公开(公告)号：US08415359B2
公开(公告)日：2013-04-09
申请号：US13198819
申请日：2011-08-05
申请人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
发明人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
IPC分类号： A61K31/497 , A61K31/4439 , A61K31/443 , A61K31/428 , A61K31/427 , A61K31/421 , A61K31/4155 , A61K31/4025 , A61K31/40 , C07D401/14 , C07D401/12 , C07D413/04 , C07D413/14 , C07D277/62 , C07D277/20 , C07D263/08 , C07D263/30 , C07D403/04 , C07D403/14 , C07D207/323
CPC分类号： C07D413/14 , C07D207/333 , C07D207/335 , C07D207/337 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D417/14
摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
摘要翻译：本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成取代具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同）或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

5. 发明授权

US06560723B1 Automatic communication protocol test system with message/sequence edit function and test method using the same 失效
标题翻译：具有消息/序列编辑功能的自动通信协议测试系统及使用相同的测试方法
公开(公告)号：US06560723B1
公开(公告)日：2003-05-06
申请号：US09472160
申请日：1999-12-27
申请人： Yumi Matsui
发明人： Yumi Matsui
IPC分类号： H02H305
CPC分类号： H04L43/50
摘要： A line monitoring function unit collects message information and sequence information from an existing communication network. A data analyzing function unit converts the collected message information and sequence information into significant information defined for each communication protocol to analyze detailed information on the communication protocol. A scenario creating function unit creates/edits a test scenario and test message with the detailed information obtained by the data analyzing function unit. A data converting function unit converts the data from the scenario creating function unit. A test message input/output function unit executes a communication protocol test in accordance with a sequence of the test scenario obtained from the scenario creating function unit. A log buffer accumulates log information collected during the communication protocol test. An edit searching function unit accesses the scenario creating function unit to obtain a scenario of interest with a search keyword for edit of the information obtained at the scenario creating function unit.
摘要翻译：线路监控功能单元从现有通信网络收集消息信息和序列信息。数据分析功能单元将收集的消息信息和序列信息转换成为每个通信协议定义的重要信息，以分析关于通信协议的详细信息。场景创建功能单元利用数据分析功能单元获得的详细信息创建/编辑测试场景和测试消息。数据转换功能单元转换来自脚本创建功能单元的数据。测试消息输入/输出功能单元根据从场景创建功能单元获得的测试场景的顺序执行通信协议测试。日志缓冲区累积在通信协议测试期间收集的日志信息。编辑搜索功能单元访问场景创建功能单元，以获得用于编辑在场景创建功能单元获得的信息的搜索关键字感兴趣的场景。

6. 发明授权

US09127070B2 Anti-DR5 antibodies, polynucleotides and methods 有权
标题翻译：抗DR5抗体，多核苷酸和方法
公开(公告)号：US09127070B2
公开(公告)日：2015-09-08
申请号：US13881645
申请日：2011-10-27
申请人： Toshiaki Ohtsuka , Takeshi Takizawa , Akiko Oguni , Tatsuji Matsuoka , Hiroko Yoshida , Yumi Matsui
发明人： Toshiaki Ohtsuka , Takeshi Takizawa , Akiko Oguni , Tatsuji Matsuoka , Hiroko Yoshida , Yumi Matsui
IPC分类号： A61K39/395 , C12N5/10 , C12N15/13 , C07K16/28 , C07K16/30 , C07K14/705 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/555 , A61K31/439 , A61K31/4545 , A61K31/513 , A61K39/00
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/439 , A61K31/4545 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/555 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K16/30 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/73 , C07K2317/92 , C07K2319/30 , A61K2300/00
摘要： The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis.[Object]An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer.[Means for Resolution]A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.
摘要翻译：本发明涉及对癌症，自身免疫性疾病或炎性疾病具有治疗作用的抗体。也就是说，本发明涉及通过凋亡显示对含有表达死亡结构域的受体表达细胞的细胞毒性活性的抗体。本发明的目的是提供对癌症具有治疗作用的药物。 [解决方法]能够诱导细胞凋亡的新型抗DR5抗体比目前可用的抗DR5抗体具有更强的细胞毒性活性。

7. 发明申请

US20140004120A1 NOVEL ANTI-DR5 ANTIBODY 有权
标题翻译：新型抗-DR5抗体
公开(公告)号：US20140004120A1
公开(公告)日：2014-01-02
申请号：US13881645
申请日：2011-10-27
申请人： Toshiaki Ohtsuka , Takeshi Takizawa , Akiko Oguni , Tatsuji Matsuoka , Hiroko Yoshida , Yumi Matsui
发明人： Toshiaki Ohtsuka , Takeshi Takizawa , Akiko Oguni , Tatsuji Matsuoka , Hiroko Yoshida , Yumi Matsui
IPC分类号： C07K16/30 , A61K31/439 , A61K39/395 , A61K31/555 , A61K31/513 , A61K31/337 , A61K31/4545
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/439 , A61K31/4545 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/555 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/70578 , C07K16/30 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/73 , C07K2317/92 , C07K2319/30 , A61K2300/00
摘要： The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis.[Object]An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer.[Means for Resolution]A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.
摘要翻译：本发明涉及对癌症，自身免疫性疾病或炎性疾病具有治疗作用的抗体。也就是说，本发明涉及通过凋亡显示对含有表达死亡结构域的受体表达细胞的细胞毒性活性的抗体。本发明的目的是提供对癌症具有治疗作用的药物。 [解决方法]能够诱导细胞凋亡的新型抗DR5抗体比目前可用的抗DR5抗体具有更强的细胞毒性活性。

8. 发明申请

US20120022075A1 NOVEL PHENYLPYRROLE DERIVATIVE 有权
标题翻译：新颖的灵性衍生物
公开(公告)号：US20120022075A1
公开(公告)日：2012-01-26
申请号：US13198819
申请日：2011-08-05
申请人： Akihiro FURUKAWA , Takehiro FUKUZAKI , Yukari ONISHI , Hideki KOBAYASHI , Takeshi HONDA , Yumi MATSUI , Masahiro KONISHI , Kenjiro UEDA , Tetsuyoshi MATSUFUJI
发明人： Akihiro FURUKAWA , Takehiro FUKUZAKI , Yukari ONISHI , Hideki KOBAYASHI , Takeshi HONDA , Yumi MATSUI , Masahiro KONISHI , Kenjiro UEDA , Tetsuyoshi MATSUFUJI
IPC分类号： A61K31/497 , C07D401/04 , C07D263/32 , C07D207/323 , A61P3/10 , C07D409/14 , A61K31/427 , A61K31/4439 , A61K31/422 , A61K31/40 , C07D277/28 , C07D241/02
CPC分类号： C07D413/14 , C07D207/333 , C07D207/335 , C07D207/337 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D417/14
摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
摘要翻译：本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成取代具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同）或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

9. 发明授权

US08017610B2 Phenylpyrrole derivative 有权
标题翻译：苯基吡咯衍生物
公开(公告)号：US08017610B2
公开(公告)日：2011-09-13
申请号：US12843348
申请日：2010-07-26
申请人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
发明人： Akihiro Furukawa , Takehiro Fukuzaki , Yukari Onishi , Hideki Kobayashi , Takeshi Honda , Yumi Matsui , Masahiro Konishi , Kenjiro Ueda , Tetsuyoshi Matsufuji
IPC分类号： A61K31/501 , A61K31/497 , A61K31/443 , A61K31/421 , C07D403/14 , C07D413/14 , C07D265/08
CPC分类号： C07D413/14 , C07D207/333 , C07D207/335 , C07D207/337 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D417/14
摘要： The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula —V—NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].
摘要翻译：本发明涉及具有优异的葡糖激酶活化活性的化合物或其药理学上可接受的盐，并且是通式（I）表示的化合物或其药理学上可接受的盐：[其中，A表示例如氧原子或硫原子，R1表示例如C1-C6烷基，C1-C6烷氧基或C1-C6卤代烷基，A和R1与与其结合的碳原子一起形成可以被 1至3个独立地选自取代基组α的基团，R 2表示可以被独立地选自取代基组α的1至5个基团取代的苯基或可被1至3个基团取代的杂环基独立地选自取代基组α，R3表示羟基或C1-C6烷氧基，取代基组α由例如卤素原子，C1-C6烷基，C1-C6烷基组成取代具有1或2个羟基，C1-C6烷基磺酰基和由式-V-NR5R6表示的基团（其中，V表示羰基或磺酰基，R5和R6可以相同）或不同，分别表示氢原子或C1-C6烷基，或R5和R6与键合的氮原子一起形成可以被1或2个基团独立地取代的4至6元饱和杂环选自C 1 -C 6烷基和羟基，并且4至6元饱和杂环可以进一步含有一个氧原子或氮原子）]。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式